Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.

Clapham HE, Rodriguez-Barraquer I, Azman AS, Althouse BM, Salje H, Gibbons RV, Rothman AL, Jarman RG, Nisalak A, Thaisomboonsuk B, Kalayanarooj S, Nimmannitya S, Vaughn DW, Green S, Yoon IK, Cummings DA.

J Infect Dis. 2016 May 1;213(9):1428-35. doi: 10.1093/infdis/jiv759. Epub 2015 Dec 23.

2.

Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.

Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E.

MBio. 2017 Sep 19;8(5). pii: e01205-17. doi: 10.1128/mBio.01205-17.

3.

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. Epub 2016 Jan 4.

4.

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.

Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, Nisalak A, Khuntirat B, Jarman RG, Fernandez S, Thomas SJ, Scott TW, Rothman AL, Yoon IK.

PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3230. doi: 10.1371/journal.pntd.0003230. eCollection 2014 Oct.

6.

Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E.

PLoS Negl Trop Dis. 2013 Jun 13;7(6):e2274. doi: 10.1371/journal.pntd.0002274. Print 2013.

7.

A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model.

Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ.

PLoS Med. 2009 Oct;6(10):e1000171. doi: 10.1371/journal.pmed.1000171. Epub 2009 Oct 27.

8.

Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort.

Corbett KS, Katzelnick L, Tissera H, Amerasinghe A, de Silva AD, de Silva AM.

J Infect Dis. 2015 Feb 15;211(4):590-9. doi: 10.1093/infdis/jiu481. Epub 2014 Oct 21.

9.

Serotype-specific and cross-reactive neutralizing antibody responses in cynomolgus monkeys after infection with multiple dengue virus serotypes.

Ito M, Katakai Y, Ono F, Akari H, Mukai RZ, Takasaki T, Kotaki A, Kurane I.

Arch Virol. 2011 Jun;156(6):1073-7. doi: 10.1007/s00705-011-0959-2. Epub 2011 Mar 16.

PMID:
21409446
10.

[Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].

Hu D, Li J, Wang D, DI B, Qiu L, Wang Y, Ding X, Che X.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Dec;32(12):1773-6, 1791. Chinese.

PMID:
23268408
11.

Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.

Ly MHP, Moi ML, Vu TBH, Tun MMN, Saunders T, Nguyen CN, Nguyen AKT, Nguyen HM, Dao TH, Pham DQ, Nguyen TTT, Le TQM, Hasebe F, Morita K.

BMC Infect Dis. 2018 Jan 10;18(1):31. doi: 10.1186/s12879-017-2894-7.

12.

Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.

Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK.

PLoS Negl Trop Dis. 2013 Sep 19;7(9):e2451. doi: 10.1371/journal.pntd.0002451. eCollection 2013.

13.

Symptomatic versus inapparent outcome in repeat dengue virus infections is influenced by the time interval between infections and study year.

Montoya M, Gresh L, Mercado JC, Williams KL, Vargas MJ, Gutierrez G, Kuan G, Gordon A, Balmaseda A, Harris E.

PLoS Negl Trop Dis. 2013 Aug 8;7(8):e2357. doi: 10.1371/journal.pntd.0002357. eCollection 2013.

14.

High frequency of pre-existing neutralizing antibody responses in patients with dengue during an outbreak in Central Brazil.

de Teive E Argolo AF, de Rezende Féres VC, Cordeiro MT, da Silveira LA, Guilarde AO, de Azevedo Marques ET Jr, de Souza WV, Martelli CM.

BMC Infect Dis. 2016 Oct 7;16(1):546.

15.

Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.

Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY.

J Virol. 2014 Sep;88(18):10813-30. doi: 10.1128/JVI.00810-14. Epub 2014 Jul 9.

16.

Dissecting the human serum antibody response to secondary dengue virus infections.

Patel B, Longo P, Miley MJ, Montoya M, Harris E, de Silva AM.

PLoS Negl Trop Dis. 2017 May 15;11(5):e0005554. doi: 10.1371/journal.pntd.0005554. eCollection 2017 May.

17.

The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.

Prompetchara E, Ketloy C, Keelapang P, Sittisombut N, Ruxrungtham K.

Asian Pac J Allergy Immunol. 2015 Sep;33(3):182-8. doi: 10.12932/AP0508.33.3.2015.

18.

Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.

de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM.

PLoS Pathog. 2014 Oct 2;10(10):e1004386. doi: 10.1371/journal.ppat.1004386. eCollection 2014 Oct.

19.

Dengue antibody in Thai children from maternally transferred antibody to acquired infection.

Pengsaa K, Limkittikul K, Yoksan S, Wisetsing P, Sabchareon A.

Pediatr Infect Dis J. 2011 Oct;30(10):897-900. doi: 10.1097/INF.0b013e31821f07f6.

PMID:
21552182
20.

Inferring the serotype associated with dengue virus infections on the basis of pre- and postinfection neutralizing antibody titers.

van Panhuis WG, Gibbons RV, Endy TP, Rothman AL, Srikiatkhachorn A, Nisalak A, Burke DS, Cummings DA.

J Infect Dis. 2010 Oct 1;202(7):1002-10. doi: 10.1086/656141.

Supplemental Content

Support Center